Dragonfly Therapeutics to Present Groundbreaking Preclinical Data on DF6215 and DF9001 at SITC 2024

 a clinical-stage biotechnology company developing novel immunotherapies, announced the company will deliver poster presentations at the Society for I...

November 08, 2024 | Friday | News
Gilead Sciences to Present Groundbreaking HIV Research at HIV Glasgow 2024, Highlighting Advances in Treatment and Prevention

Gilead Sciences, Inc. (Nasdaq: GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infe...

November 08, 2024 | Friday | News
FDA Grants Orphan Drug and Rare Pediatric Disease Designations to Ifetroban for Duchenne Muscular Dystrophy Cardiomyopathy

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced  that the United States (U.S.) Food and D...

November 07, 2024 | Thursday | News
bluebird bio to Present New Data on Gene Therapies for Sickle Cell Disease and Beta-Thalassemia at ASH 2024

bluebird bio, Inc. (Nasdaq: BLUE) announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell ...

November 06, 2024 | Wednesday | News
Genentech Publishes Positive Phase III Results for Itovebi in Advanced Breast Cancer in NEJM

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that a detailed analysis of the positive Phase III INAVO120 results, evaluat...

November 01, 2024 | Friday | News
AbbVie and EvolveImmune Forge Partnership to Develop Next-Gen Cancer Therapies

AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic c...

November 01, 2024 | Friday | News
GSK Acquires CMG1A46 from Chimagen for $300 Million to Target B Cell-Driven Autoimmune Diseases

GSK plc (LSE/NYSE: GSK) and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a c...

October 30, 2024 | Wednesday | News
RemeGen's Taicercept® for Generalized Myasthenia Gravis Receives Priority Review from China’s Drug Administration

RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced that the marketing applica...

October 29, 2024 | Tuesday | News
Jubilant Therapeutics Advances Innovative Cancer Therapies with First Patient Dosing in Global Trials for JBI-802 and JBI-778

JBI-802 is a first-in-class, orally administered, inhibitor of CoREST complex JBI-778 is a potential best-in-class, orally ad...

October 28, 2024 | Monday | News
RiboX Therapeutics Secures FDA Clearance for First-Ever Circular RNA Therapy RXRG001 in Phase I/IIa Study

RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics...

October 28, 2024 | Monday | News
Regeneron and Sanofi Present Positive Phase 3 Results for Dupixent in Chronic Spontaneous Urticaria

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi will present positive data from the Phase 3 LIBERTY-CUPID Study C evaluating the inves...

October 25, 2024 | Friday | News
Positive Phase 3 Results for Dupixent in Chronic Spontaneous Urticaria to be Unveiled at ACAAI 2024

Positive data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent (dupilumab) in biologic-naive patients with uncontrolle...

October 25, 2024 | Friday | News
European Commission Approves KEYTRUDA for New Indications in Gynecologic Cancers

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved two new indications for K...

October 25, 2024 | Friday | News
PolTREG’s Early Treatment with PTG-007 Could Offer Functional Cure for Children at Risk of Type 1 Diabetes

Treating diabetes patients earlier with PTG-007 could provide functional cure Recruitment will go ahead after European Medicines Agency approval Comp...

October 24, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close